NEW YORK (GenomeWeb) – Asuragen today announced it has received a clinical laboratory permit from New York state to offer the company's Xpansion Interpreter and miRInform Thyroid tests in the state.

The Austin, Texas-based firm can now offer the tests in all 50 states in the US, it said.

Xpansion Interpreter is a reflex test for fragile X carriers. It determines the total number of CGG repeats and number of AGG interruptions in the Fragile X Mental Retardation gene and can help determine the risk for potential parents of having a child with fragile X syndrome.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.